Literature DB >> 2126695

In vitro activity of dirithromycin (LY 237216) compared with activities of other macrolide antibiotics.

K W Yu1, H C Neu.   

Abstract

Dirithromycin inhibited Streptococcus pyogenes, Streptococcus pneumoniae, and other hemolytic streptococci at concentrations of less than or equal to 0.03 to 0.12 micrograms/ml, with 90% inhibition at 0.12 micrograms/ml, which is comparable to results using erythromycin. Group A streptococci, listeriae, and enterococci resistant to erythromycin were resistant to dirithromycin. Erythromycin-susceptible staphylococci were inhibited by 0.5 micrograms/ml, but for erythromycin-resistant isolates MICs were greater than or equal to 8 micrograms/ml. For Haemophilus influenzae, MICs were greater than or equal to 8 micrograms/ml, two- to fourfold greater than for erythromycin. The activity of dirithromycin against staphylococci and streptococci was not decreased by the addition of human serum.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2126695      PMCID: PMC171944          DOI: 10.1128/AAC.34.9.1839

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

Review 1.  New directions for macrolide antibiotics: structural modifications and in vitro activity.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria.

Authors:  T Barlam; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

3.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

4.  Susceptibility of Campylobacter jejuni and Campylobacter coli to macrolides and related compounds.

Authors:  Z Elharrif; F Mégraud; A M Marchand
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

5.  Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.

Authors:  D J Hardy; D M Hensey; J M Beyer; C Vojtko; E J McDonald; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

Review 6.  Erythromycin: a microbial and clinical perspective after 30 years of clinical use (2).

Authors:  J A Washington; W R Wilson
Journal:  Mayo Clin Proc       Date:  1985-04       Impact factor: 7.616

Review 7.  New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

  7 in total
  6 in total

1.  Comparison of dirithromycin and penicillin for treatment of streptococcal pharyngitis.

Authors:  V S Watkins; M Smietana; P M Conforti; G D Sides; W Huck
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

Review 2.  Choosing the right macrolide antibiotic. A guide to selection.

Authors:  L Charles; J Segreti
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

3.  Synthesis and antimicrobial evaluation of dirithromycin (AS-E 136; LY237216), a new macrolide antibiotic derived from erythromycin.

Authors:  F T Counter; P W Ensminger; D A Preston; C Y Wu; J M Greene; A M Felty-Duckworth; J W Paschal; H A Kirst
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

4.  In vitro activity of dirithromycin against Chlamydia trachomatis.

Authors:  J Segreti; K S Kapell
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

5.  Penetration of cefprozil into middle ear fluid of patients with otitis media.

Authors:  W C Shyu; J Haddad; J Reilly; W N Khan; D A Campbell; Y Tsai; R H Barbhaiya
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

Review 6.  Dirithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D H Peters
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.